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Abstract 
BACKGROUND: Drug-induced carcinogenesis is a matter of huge popularity and the subject of in-depth research 
over the last few years. According to the literature, dopamine agonists and acetylsalicylic acid fall into the list of 
drugs likely to potentiate the development of cutaneous melanoma. However, according to recent data, widely 
used angiotensin receptor blockers (ARBs) for the treatment of arterial hypertension, also carry a risk of 
malignancy development. The content of probable carcinogens, such as NDMA or NDEA in the drug valsartan 
(ARBs), causes the product to be withdrawn from the market. Recent experimental data suggest that another 
angiotensin receptor blocker-losartan also stimulates cell adhesion and melanoma cell invasion. 
CASE REPORT: We present a 70-year-old patient who has been on systemic therapy with a combined drug of 
amlodipine and valsartan since 2008 and only valsartan from 2015. Three years after the first intake of valsartan 
(2011), the patient developed a pigment lesion on the right arm. Approximately 2.5 years after doubling the dose 
of valsartan, the patient observed a progression in the size of the lesion, which was the cause of the 
dermatological examination and hospitalisation for surgical removal. The melanocytic lesion was removed by 
radical excision and a surgical field of 0.5 cm in all directions, followed by histological verification, which found the 
presence of cutaneous melanoma with a tumour thickness of 3 mm. A re-excision was planned with an additional 
surgical field of 1.5 cm in all directions combined with parallel removal of a draining lymph node. 
CONCLUSION: The case is indicative of two things: 1) the possible triggering of melanoma within the systemic 
treatment with valsartan; and 2) the necessity for optimization of melanoma surgery within the one-step 
melanoma surgery, which in this case would result in a single surgical excision of the primary lesion, with an 
operational security field of 2 cm in all directions, along with the removal of a draining lymph node. 
 
 
 
 
Introduction 
 
Numerous data suggest that malignant 
melanoma may be drug-induced, and various 
mechanisms are likely to potentiate directly or 
indirectly carcinogenesis [1], [2], [3], [4], [5]. According 
to the number of publications in patients with 
schizophrenia and Parkinson's, the risk of melanoma 
is probably determined by blood levels of dopamine 
[1], [2]. Induction of malignant melanoma by 
acetylsalicylic acid has also been the subject of 
studies, and it is currently thought that men taking 
Aspirin on a daily basis are at an increased risk of 
developing melanoma [3]. According to the latest in 
vitro data, valsartan and losartan may also potentiate 
carcinogenesis [4], [5]. 
We describe a first official case of possible 
valsartan-induced melanoma following administration 
of an angiotensin receptor blocker- valsartan, 
produced by a company still on the market and not on 
the list of withdrawn products. 
 
 
Case Report 
 
We present a 70-year-old man, skin 
phototype II, no history of excessive exposure to UV 
light and no history of malignancy in the family. The 
patient suffers from arterial hypertension, which he 
controls through medication. The systemic cardiologic 
therapy started with a combined drug of amlodipine 
and valsartan (10/160 mg), once daily (1-0-0), from 
2008 to 2018. Due to unsatisfactory control of 
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hypertension in 2015 additional valsartan (160mg) has 
been added to the therapy (0-0-1), which the patient is 
still receiving at the time of hospitalisation (2018). 
Three years after the first intake of amlodipine and 
valsartan (10/160 mg) (2011), the patient developed a 
pigment lesion on the right arm. Clinically and 
dermatoscopic (according to anamnestic data and the 
examinations conducted at that time) there was no 
evidence of cutaneous melanoma, and surgical 
treatment was not recommended. However, in 2015, 
the dose of valsartan was duplicated. Two and a half 
years later (2018), the patient observed gradual 
change in the size of the lesion, discomfort, small 
bleeding, and sensitivity in the area of the lesion.  
Reason for hospitalisation of the patient is the 
progressive increase in the size of the lesion and 
bleeding observed from its surface over the last few 
days (Figure 1А). During the dermatological 
examination, in the area of the right arm, we found the 
presence of a melanocytic lesion with an uneven 
surface, a nodular component, uneven borders and 
partly a bleeding surface, clinically suspect to 
malignant melanoma (Figure 1А). The lesion was 
removed by elliptical excision, with an operative safety 
margin of 0.5 cm in all directions (Figure 1B and 1C). 
The surgical defect was closed by a single interrupted 
sutures (Figure 1D). The subsequent histological 
study showed that it is superficial nodular malignant 
melanoma, Clark’s level III, Breslow’s thickness- 3 
mm, high mitotic activity and ulceration; abundant 
lymphocytic stromal reaction; resection lines-no 
infiltration.  
 
Figure 1: A) Clinical view of the melanocytic lesion with black 
colour, nodular component and partially bleeding surface; B) 
Intraoperative finding of the lesion removed by elliptical excision; C) 
Intraoperative finding of ligation of the blood vessels; D) 
Postoperative clinical picture of surgical defect closed by single 
interrupted sutures 
 
Staging showed that it was a malignant 
melanoma stage IIB (T3bN0M0). The follow-up 
screening and the PET scan conducted detected the 
presence of a pathologically enlarged lymph node in 
the right axilla (suspected for metastatic), with 
dimensions 6/10 mm. Lymphatic scintigraphy was 
conducted, which confirmed the findings from the Pet 
Scan. A re-excision was performed with an operative 
safety margin of 1.5 cm in all directions, combined 
with removal of a draining lymph node and axillary 
lymphadenectomy on the right axilla. A single 
metastatic lymph node was established histologically; 
therefore the stage was defined as IIIC (T3bN1M0). A 
plan was prepared for 1) monthly control review, 2) 
monthly immunotherapy (vaccines) and 3) abdominal 
ultrasound at 6 months and once a year (in the winter) 
X-ray of the lung. 
 
 
Discussion 
 
Valsartan belongs to a group of medicines 
called angiotensin receptor blockers (ARBs) that are 
widely used to treat arterial hypertension [4]. 
According to randomised controlled trials, this group 
of blockers is associated with an increased risk of 
developing cancer, but the individual risk of any drug 
in this group is not yet known [4]. Lately, research has 
been increasing on the role of the renin-angiotensin 
system, and more specifically angiotensin II type 1 
and type 2 receptors in the regulation of cell 
proliferation, angiogenesis and tumour progression 
[4]. As malignancy, malignant melanoma also falls 
within the scope of studies about the likelihood of 
being induced by ARBs [5]. The alleged carcinogenic 
effect of valsartan is first announced by the US 
manufacturer, Prinston Pharmaceuticals Inc., which in 
June 2018 informed the Food and Drug Administration 
(FDA) that it stopped the production of valsartan-
containing products because it detected traces of N-
nitrosodimethylamine (NDMA) in the active 
pharmaceutical ingredient of valsartan (API) provided 
by a Chinese manufacturer (Zhejiang Huahai 
Pharmaceutical Co) [6]. NDMA is classified as a 
chemical that belongs to the family of potent 
carcinogens and is used for the production of rocket 
fuel, softeners and other products [7]. According to the 
US Department of Health and Human Services, 
exposure to high doses of NDMA may cause liver 
damage, and NDMA is a likely human carcinogen [8]. 
Animal studies have shown that NDMA can cause 
tumours in the liver, kidneys and the respiratory tract, 
making it potentially harmful for humans as well [8]. 
Subsequently, the European and American health 
services have expanded the withdrawal of valsartan 
after detection of NDMA in medicines manufactured 
by a second Chinese pharmaceutical manufacturer 
(Zhejiang Tianyu Pharmaceuticals of Taizhou) and by 
a manufacturer in India (Hetero Labs Limited, Camber 
Pharmaceuticals) [9]. Although the FDA declares that 
not all drugs containing the NDMA ingredient are 
potentially dangerous, several companies voluntarily 
withdraw their products with valsartan (Major 
Pharmaceuticals, Solco Healthcare and Teva 
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Pharmaceuticals Industries, as well as 
valsartan/hydrochlorothiazide from Solco and Teva) 
[10]. In September 2018, information on a second 
potential carcinogen in the product valsartan-N-
nitrosodiethylamine (NDEA) was published [11]. An 
important publication from 2018 explains the possible 
mechanism by which angiotensin receptor blockers 
(ARBs), particularly losartan, are involved in the 
pathogenesis of development of malignant melanoma 
[5]. It postulates that losartan inhibits the activity of 
NHE1 (Na+/H+ exchanger isoform 1) and migration of 
human melanoma cells (MV3), but at the same time 
stimulates MV3 cell adhesion and invasion [5]. 
The case presented by us poses several 
interesting questions: the newly discovered 
melanocytic lesion occurred 3 years after the first 
intake of valsartan, as in the last 2-3 years (2015-
2018), the patient observed an increase in its size, 
which coincides with the introduction of a second 
product containing valsartan (of the same 
pharmaceutical company). The inevitable association 
that occurs is that the progression of melanoma and 
the likelihood of developing metastases may be dose-
dependent [12]. In fact, according to the FDA, on a 
daily intake of the highest dose of valsartan (320 mg) 
throughout 4 years, 1/8000 patients are likely to 
develop cancer, which, according to the FDA, is 
sufficient reason to withdraw products (containing 
NDMA) [12]. An open question remains whether the 
cause lies in NDMA, NDEA or other carcinogens? Or 
the generic itself? 
According to officially shared data from EMA 
(European Medicines Agency, within our electronic 
correspondence), there are already 9 reported cases 
of melanoma in patients taking valsartan, but none of 
them is officially disclosed. Interestingly, these cases 
are most likely of valsartan contaminated with NDMA 
(?) Or drugs that are in the FDA’s prohibited lists? 
While missing detailed EMA data, we present a case 
with valsartan intake, produced in Germany! A product 
that is still on the market and does not fall into the list 
of withdrawn products (produced by a company 
belonging to the top 10 pharmaceutical giants). This 
means that the carcinogenic effect may not only be 
related to the presence or contamination with NDMA 
but may come directly from the generic substance of 
valsartan (?) [5)] as well as from the presence of a 
potential another carcinogen [11]. It should not be 
excluded that the onset of melanoma and the 
systemic administration of valsartan may be just a 
mere coincidence. 
It should be noted that older patients, 
especially men over 65, are at increased risk of 
developing melanoma [13]. Also, it is believed that 50 
years of age and older men are more often diagnosed 
with melanomas with a thickness ≥ 2.0 mm and that 
with increasing age, more frequently arise de novo 
melanomas [13]. Shared information is not an 
indictment to the respective manufacturer, but 
contains important clinical observations and analyses 
based on experimental data in the world literature, as 
well as from the previously recorded cases of 
melanomas in patients receiving valsartan -data 
shared by EMA. 
In conclusion, this case reaches important 
conclusions, indicating that the systemic intake of 
valsartan may trigger the development of malignant 
melanoma and the likelihood of its progression being 
directly proportional to the dose. One step melanoma 
surgery, in this case, would be a good therapeutic 
solution providing removal of the lesion in one surgical 
session along with the removal of a draining lymph 
node. 
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